Tirzepatide vs Retatrutide
Head-to-head comparison of Tirzepatide and Retatrutide for research applications. Both peptides are studied for Weight Management and Metabolic Health, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Category | Metabolic / Dual GIP-GLP-1 Agonist | Metabolic / Triple Agonist |
| Mechanism | Tirzepatide (MW ~4813 g/mol, C225H348N48O68) simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon... |
| Evidence Rating | A — FDA Approved | B — Phase III / NDA Filed |
| Clinical Status | FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA) | Phase 3 clinical trials (Eli Lilly TRIUMPH program) |
| Safety Profile | Common (5%+ in trials): abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, GERD, hair loss, hypersensitivity reactions, injection site reactions, nausea, vomiting; Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems | GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate; GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) |
| Route | Subcutaneous | Subcutaneous (clinical trial formulation only) |
| Dose Range | 2.5–15 mg/week, titrated every 4 weeks | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 |
| Frequency | Once weekly | Once weekly |
| Molecular Weight | ~4813.5 g/mol | N/A |
| Half-Life | ~5 days (116 hours) | ~6 days (allows once-weekly dosing) |
Overview
Tirzepatide and Retatrutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Tirzepatide — Mechanism & Evidence
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly, FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) including severe obstructive sleep apnea in adults with obesity. It is a 39-amino-acid peptide with a C20 fatty di-acid moiety that promotes albumin binding, enabling once-weekly dosing. Clinical trials consistently demonstrate it delivers the most substantial weight reduction among incretin-based therapies, with up to 22.5% mean body weight loss at 72 weeks.
Key claims: Superior weight loss compared to semaglutide; Improves blood sugar control; May improve liver fat / NASH.
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Tirzepatide 10mg
10mg
Retatrutide — Mechanism & Evidence
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. In the Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), the 12 mg dose achieved 24.2% mean body weight reduction at 48 weeks, with 100% of participants achieving at least 5% weight loss. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Key claims: Unprecedented weight loss in Phase 2; Phase 3 confirms efficacy with osteoarthritis benefit; Improves glycemic control in type 2 diabetes.
Shared Research Applications
Both peptides are studied for: Weight Management, Metabolic Health.
Tirzepatide is also researched for: no additional unique applications.
Retatrutide is also researched for: no additional unique applications.
Safety Considerations
Tirzepatide: Common (5%+ in trials): abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, GERD, hair loss, hypersensitivity reactions, injection site reactions, nausea, vomiting Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems FDA boxed warning for thyroid C-cell tumors (rodent data); call doctor for neck lump, swallowing difficulty, hoarseness, or shortness of breath
Retatrutide: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Shop Research Peptides
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Tirzepatide 10mg
10mg
BPC-157 5mg
5mg
Ipamorelin 10mg
10mg
Semaglutide 10mg
10mg
TB-500 5mg
5mg
GHK-Cu 50mg
50mg
Sermorelin 5mg
5mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tirzepatide vs Retatrutide: Evidence, Mechanisms, Safety
This reference distinguishes randomized trial evidence from extrapolation for tirzepatide and retatrutide, clarifying mechanisms and safety. It highlights the absence of direct head-to-head trials and the limits of current data.
Retatrutide in Canada: Access, Trials, and Approval Timing
Retatrutide is not yet approved in Canada; access is limited to clinical trials. This article outlines the current status, evidence, and realistic timelines for availability.
Eli Lilly sues pharmacies over early retatrutide sales: retatrutide news
Eli Lilly is taking legal action against pharmacies and peptide vendors for selling retatrutide before approval. This retatrutide news highlights the growing tension between pharmaceutical IP protection and the peptide research market.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe